Globus Medical (GMED) Q4 FY25 earnings call

Globus Medical delivered a record Q4 FY25, driven by strong U.S. Spine performance and a rebound in Enabling Technologies sales, exceeding synergy targets for NuVasive and achieving early EPS accretion from Nevro. The company is now focused on sustained profitable growth through increased R&D investment, aggressive capital placement strategies, and further integration of its recent acquisitions, while acknowledging potential short-term lumpiness in the Nevro business and continued efforts in international markets.